Daniel Everitt
Overview
Explore the profile of Daniel Everitt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1062
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Conradie F, Bagdasaryan T, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al.
N Engl J Med
. 2022 Sep;
387(9):810-823.
PMID: 36053506
Background: The bedaquiline-pretomanid-linezolid regimen has been reported to have 90% efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events with 1200 mg of linezolid daily has been high....
2.
Gomez G, Siapka M, Conradie F, Ndjeka N, Garfin A, Lomtadze N, et al.
BMJ Open
. 2021 Dec;
11(12):e051521.
PMID: 34862287
Objectives: Patients with highly resistant tuberculosis have few treatment options. Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months. We present...
3.
Abdelwahab M, Court R, Everitt D, Diacon A, Dawson R, Svensson E, et al.
Antimicrob Agents Chemother
. 2021 Apr;
65(7):e0268720.
PMID: 33875426
Clofazimine is classified as a WHO group B drug for the treatment of rifampin-resistant tuberculosis. QT prolongation, which is associated with fatal cardiac arrhythmias, is caused by several antitubercular drugs,...
4.
Li M, Saviolakis G, El-Amin W, Makhene M, Osborn B, Nedelman J, et al.
Clin Pharmacol Drug Dev
. 2020 Dec;
10(6):634-646.
PMID: 33378139
Tuberculosis (TB) continues to be a serious threat to public health throughout the world. Newer treatments are needed that could offer simplified regimens with activity against both drug-sensitive and drug-resistant...
5.
Nedelman J, Salinger D, Subramoney V, Woolson R, Wade K, Li M, et al.
Antimicrob Agents Chemother
. 2020 Oct;
65(1).
PMID: 33077660
Pretomanid was approved by the U.S. FDA, via the limited population pathway for antibacterial and antifungal drugs, as part of a three-drug regimen with bedaquiline and linezolid for the treatment...
6.
Abdelwahab M, Wasserman S, Brust J, Gandhi N, Meintjes G, Everitt D, et al.
J Antimicrob Chemother
. 2020 Aug;
75(11):3269-3277.
PMID: 32747933
Background: Clofazimine is in widespread use as a key component of drug-resistant TB regimens, but the recommended dose is not evidence based. Pharmacokinetic data from relevant patient populations are needed...
7.
Conradie F, Everitt D, Crook A
N Engl J Med
. 2020 Jun;
382(24):2377.
PMID: 32521143
No abstract available.
8.
Diacon A, De Jager V, Dawson R, Narunsky K, Vanker N, Burger D, et al.
Antimicrob Agents Chemother
. 2020 May;
64(7).
PMID: 32366714
No abstract available.
9.
Conradie F, Diacon A, Ngubane N, Howell P, Everitt D, Crook A, et al.
N Engl J Med
. 2020 Mar;
382(10):893-902.
PMID: 32130813
Background: Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes. Methods: In an open-label, single-group study in which follow-up is ongoing at...
10.
Diacon A, De Jager V, Dawson R, Narunsky K, Vanker N, Burger D, et al.
Antimicrob Agents Chemother
. 2020 Jan;
64(4).
PMID: 31988102
Linezolid is increasingly used for the treatment of tuberculosis resistant to first-line agents, but the most effective dosing strategy is yet unknown. From November 2014 to November 2016, we randomized...